Ipsen: New Target Increase to 155 Euros at Closing
Ipsen's stock fell 1.22% on Wednesday, closing at 137.70 euros after reaching 139.40 euros the day before. Nevertheless, the pharmaceutical company's stock is still up 15.23% over three months and 13.71% over a year. In this context, analysts are adjusting their targets.
This Wednesday, Deutsche Bank significantly raised its target price on Ipsen, from 135 euros to 155 euros, while maintaining a 'buy' recommendation. This increase gives the stock a potential upside of about 12.5% compared to the last recorded price. Concurrently, BNP Paribas Exane also revised its approach two days earlier, on January 26, raising its target from 105 to 115 euros. However, the bank maintains an 'underperform' rating, reflecting a more cautious stance on the stock. These adjustments indicate an ongoing reevaluation of the potential of the group, which specializes in neuroscience and oncology, as the recent stock performance shows a marked upward trend.
Technical Analysis Indicates Strong Momentum
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Technically, Ipsen is significantly above its 20-day moving average, set at 129.08 euros, indicating favorable momentum. The stock thus shows a premium of nearly 7% compared to this intermediate threshold. However, the 14-day Relative Strength Index (RSI) is in the overbought zone at 79, a level suggesting a short-term overheating and could limit the immediate progress of the stock. This situation reflects strong investor enthusiasm but also calls for caution regarding potential corrective movements. The one-month volatility stands at 9.35, reflecting moderate fluctuations in a generally upward-oriented context.
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1074.9M€
Guidance from the release
Ipsen a réalisé un excellent début d'année 2026.
Croissance soutenue grâce aux trois aires thérapeutiques.
Risks mentioned
pression réglementaire anticipée sur de nouveaux médicaments
concurrence accrue sur Somatuline à cause des génériques
Opportunities identified
croissance des ventes totales du Groupe supérieure à 13,0 %
lancement de trois nouveaux programmes en phase avancée
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
